This educational resource is for European healthcare professionals involved in the care of patients with asthma. SPIRIVA® Respimat® is approved for use in asthma in the European Union, Japan, USA and many other countries (Boehringer Ingelheim, 2015). The indication varies by country and this educational resource may contain information about medications for which indications may not be approved in your country.
The Disease Awareness section provides information regarding the impact and assessment of symptomatic asthma as well as potential management strategies.
The Treatment Strategy section contains information on the management of asthma and the available treatment classes as well as links to a number of useful asthma management guidelines.